drugset / Trial / NCT04882683
Clinical Study of Cord Blood Mononuclear Cells on Treatment of Hormone-resistant or Hormone-dependent Ulcerative Colitis
RandomizedParallel-groupOpen-labelTreatment
Summary
This study conducted a systematic clinical observation of the clinical efficacy of UCB-MNCs in the treatment of hormone-resistant or hormone-dependent ulcerative colitis, in order to observe its clinical safety and efficacy.
Timeline
- Start
- 2021-06-01
- Primary completion
- 2022-06-01
- Completion
- 2022-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Umbilical cord blood mononuclear cells | Cell therapy | 50 ml | Intravenous |
| Subject | Umbilical cord blood mononuclear cells | Cell therapy | 2e+08 cells | Intravenous |
| Background | Adalimumab | Monoclonal antibody | 40 mg | — |
| Background | Azathioprine | Small molecule | 1 mg/kg | — |
| Background | Prednisone | Other / unclassified | 0.75 mg/kg | — |